Wagmo adds Wonderdog screening tools to employee pet benefits
Bottom line
Wagmo and Wonderdog have launched a partnership that adds discounted access to Wonderdog’s canine health-tracking app and, in Los Angeles and New York City, at-home blood draws to Wagmo’s employee pet benefits. The companies said active Wagmo members can get 20% off Wonderdog’s annual app membership nationwide and 10% off Wonderdog’s at-home blood draw service in those two launch markets. Wonderdog says its platform pulls in veterinary records, tracks changes against an individual dog’s baseline, and uses a blood panel processed by Antech to monitor more than 40 biomarkers across major body systems. (wpta21.marketminute.com)
Why it matters: For veterinary professionals, the partnership is another sign that preventive diagnostics and longitudinal monitoring are moving closer to the employee-benefits and consumer health-tech space. That could increase client awareness of baseline lab work and earlier follow-up for subtle abnormalities, but it also raises familiar questions around interpretation, continuity of care, and how app-based screening fits with the veterinarian-client-patient relationship and hands-on exams. Industry guidance and lab experts have emphasized that trending values over time can support earlier detection, while at-home testing companies themselves acknowledge these tools are not a substitute for professional veterinary care. (uat.antechdiagnostics.com)
What to watch: Watch for whether Wagmo expands the offering beyond the initial cities, and whether veterinary teams begin seeing more clients arrive with app-generated trend data and outside screening results tied to employer-sponsored benefits. (wpta21.marketminute.com)
Key facts
- Companies
- Wagmo and Wonderdog
- Offer
- Discounted access to Wonderdog’s canine health-tracking app
- App discount
- 20% off annual app membership
- Blood draw discount
- 10% off at-home blood draws
- Launch markets
- Los Angeles and New York City
- Availability
- Nationwide for app membership discount
- Platform features
- Pulls in veterinary records and tracks changes against a dog’s baseline
- Lab processing
- Blood panel processed by Antech
- Biomarkers
- More than 40 biomarkers
Wagmo is adding early-disease-detection tools to its employee pet benefits through a new partnership with Wonderdog, a preventive health platform focused on dogs. Under the deal, active Wagmo members receive discounted access to Wonderdog’s annual app membership nationwide, plus discounted at-home blood draws in Los Angeles and New York City, as employers head into open enrollment. (wpta21.marketminute.com)
The move fits Wagmo’s broader strategy of positioning pet health as an employee benefit rather than just a direct-to-consumer purchase. Wagmo has built its business around employer-sponsored wellness and insurance offerings for dogs and cats, including routine care reimbursement and telehealth access, and it has previously added partner perks such as Rover discounts and benefits-administration integrations. (wagmo.io)
Wonderdog, meanwhile, is part of a growing wave of veterinary-adjacent companies trying to push preventive monitoring closer to the home. The company says its platform connects veterinary records, tracks health trends over time, and compares dogs against their own baseline rather than relying only on breed averages. In markets where its mobile service is available, Wonderdog offers at-home blood draws with urinalysis and veterinary review; the company says each panel is processed by Antech and tracks more than 40 biomarkers, with disease areas including kidney disease, heart disease, pancreatitis, inflammatory disease, Lyme disease, and some cancers. (wpta21.marketminute.com)
In the announcement, Wagmo CEO Christie Horvath framed the partnership as an open-enrollment enhancement for employers, while Wonderdog CEO Jeff Safenowitz emphasized earlier detection through data and longitudinal tracking. Wonderdog’s background also matters here: the company says it was founded in 2026, is backed by WndrCo and Maveron, and comes from the team behind Barkbus, with public-facing medical leadership that includes veterinarian Dr. Evan Antin. (wpta21.marketminute.com)
Outside the companies’ own messaging, the partnership lands in a market where enthusiasm for earlier detection is rising, but so is scrutiny around evidence, workflow, and clinical oversight. Antech’s veterinary education materials stress the value of establishing baseline values and trending results over time in apparently healthy dogs, and AAHA preventive-care materials similarly emphasize that pets often hide illness and that screening lab work can surface early changes before obvious clinical signs develop. At the same time, at-home testing providers and veterinary commentators have noted an important limitation: screening data can prompt action, but they don’t replace a physical exam or the clinical judgment needed to decide what findings are meaningful. (uat.antechdiagnostics.com)
Why it matters: For veterinary teams, this is less about one employer-benefits partnership and more about where companion-animal preventive care is heading. If employer-sponsored pet benefits begin bundling app-based monitoring, telehealth, and discounted diagnostics, clinics may see more pet parents arriving with external lab results, trend dashboards, or automated risk flags before a traditional wellness visit. That could create opportunities for earlier workups and stronger compliance with preventive recommendations, but it may also add pressure around result interpretation, medical record integration, and client expectations about what “early detection” can realistically deliver. (wpta21.marketminute.com)
The bigger question is whether these services become a referral funnel into veterinary care or a parallel layer that clinics have to absorb without reimbursement or workflow support. Much will depend on how clearly companies communicate the role of the primary veterinarian, how data are shared back to clinics, and whether outcomes data emerge to show that these programs improve timeliness of diagnosis, adherence, or cost of care rather than simply increasing testing volume. That evidence base is still developing across the broader early-detection and liquid-biopsy landscape in veterinary medicine. (aaha.org)
What to watch: Near term, watch for geographic expansion beyond Los Angeles and New York City, any published validation or outcomes data from Wonderdog, and signs that more employers use pet-health perks as an open-enrollment differentiator in 2027. (wpta21.marketminute.com)